- Home
- VEL vs XNCR Comparison
VEL vs XNCR Comparison
Compare VEL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- XNCR
- Stock Information
- Founded
- VEL 2004
- XNCR 1997
- Country
- VEL United States
- XNCR United States
- Employees
- VEL N/A
- XNCR N/A
- Industry
- VEL Finance: Consumer Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- XNCR Health Care
- Exchange
- VEL Nasdaq
- XNCR Nasdaq
- Market Cap
- VEL 602.1M
- XNCR 547.8M
- IPO Year
- VEL 2020
- XNCR 2013
- Fundamental
- Price
- VEL $18.42
- XNCR $10.03
- Analyst Decision
- VEL Buy
- XNCR Buy
- Analyst Count
- VEL 5
- XNCR 10
- Target Price
- VEL $21.20
- XNCR $20.22
- AVG Volume (30 Days)
- VEL 99.9K
- XNCR 862.2K
- Earning Date
- VEL 11-06-2025
- XNCR 11-05-2025
- Dividend Yield
- VEL N/A
- XNCR N/A
- EPS Growth
- VEL 26.95
- XNCR N/A
- EPS
- VEL 2.22
- XNCR N/A
- Revenue
- VEL $195,592,000.00
- XNCR $146,929,000.00
- Revenue This Year
- VEL $3.99
- XNCR $23.31
- Revenue Next Year
- VEL $29.69
- XNCR N/A
- P/E Ratio
- VEL $8.33
- XNCR N/A
- Revenue Growth
- VEL 44.29
- XNCR N/A
- 52 Week Low
- VEL $16.12
- XNCR $6.92
- 52 Week High
- VEL $20.98
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- VEL 46.90
- XNCR 74.51
- Support Level
- VEL $18.10
- XNCR $8.49
- Resistance Level
- VEL $18.71
- XNCR $8.73
- Average True Range (ATR)
- VEL 0.40
- XNCR 0.46
- MACD
- VEL -0.12
- XNCR 0.16
- Stochastic Oscillator
- VEL 27.08
- XNCR 94.02
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.